TITLE

Delayed onset of a second paraneoplastic neurological syndrome in eight patients

AUTHOR(S)
François Ducray
PUB. DATE
August 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Aug2010, Vol. 81 Issue 8, p937
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: The occurrence of a second delayed paraneoplastic neurological syndrome (PNS), different from the first, in the same patient, is not well known. However, recognition of this possibility is important in the management of the patient with PNS. OBJECTIVE: To describe eight patients who presented with two different PNS with a time delay of months to years. DESIGN, SETTING AND PATIENTS: Retrospective analysis of eight patients, included in the European PNS database, with two different PNS that occurred months to years apart. RESULTS: The median delay between the two different PNS was 15 months. The antibody repertoire did not change between the two episodes. Anti-Hu was detected in five patients, and anti-CV2 and anti-Ri in one each. One patient did not present onconeural antibodies. Lung cancer was diagnosed in six patients. In five patients, the second PNS revealed a cancer relapse (n=4) or a second cancer (n=1) and in three it occurred without evidence of tumour recurrence. In these three patients, all with anti-Hu antibodies, the second episode consisted of a lower motor neuron disease. Median survival was not reached after a median follow-up of 5 years. CONCLUSIONS: A second PNS can reveal a cancer relapse but can also arise in its absence. The long survival of patients with a second PNS suggests that the immune response might be more effective in controlling the cancer.
ACCESSION #
52879002

 

Related Articles

  • Recommended diagnostic criteria for paraneoplastic neurological syndromes. Graus, F.; Delattre, J. Y.; Antoine, J. C.; Dalmau, J.; Giometto, B.; Grisold, W.; Honnorat, J.; Smitt, P. Sillevis; Vedeler, Ch.; Verschuuren, J. J. G. M.; Vincent, A.; Voltz, R. // Journal of Neurology, Neurosurgery & Psychiatry;Aug2004, Vol. 75 Issue 8, p1135 

    Background: Paraneoplastic neurological syndromes (PNS) are defined by the presence of cancer and exclusion of other known causes of the neurological symptoms, but this criterion does not separate "true" PNS from neurological syndromes that are coincidental with a cancer. Objective: To provide...

  • Recommended diagnostic criteria for paraneoplastic neurological syndromes. Greenlee, J. E. // Journal of Neurology, Neurosurgery & Psychiatry;Aug2004, Vol. 75 Issue 8, p1090 

    This article focuses on recommended diagnostic criteria for paraneoplastic neurological syndromes. Paraneoplastic neurological syndromes are remote complications of systemic malignancy, characterized clinically by subacute progression to profound neurological disability and pathologically by...

  • Hu, Yo, Ri, Ma, Ta: monosyllabic answers to complex questions. Verschuuren, Jan // Journal of Neurology, Neurosurgery & Psychiatry;Jul2008, Vol. 79 Issue 7, p742 

    The article comments on a paper by L. A. Hoffman and colleagues which provides a detailed description of the neurological presentation of patients with anti-Ma or anti-Ta antibodies by expanding the spectrum of paraneoplastic neurological diseases. According to the author, Anti-Ma or anti-Ta...

  • Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo). Totland, Cecilie; Bredholt, Geir; Haugen, Mette; Haukanes, Bjørn Ivar; Vedeler, Christian A. // Cancer Immunology, Immunotherapy;Feb2010, Vol. 59 Issue 2, p231 

    Patients with cancer may develop paraneoplastic neurological syndromes (PNS) in which onconeural antibodies are important diagnostic findings. As the functional role of onconeural antibodies is largely unknown, insight gained by identifying associated antibodies may help to clarify the...

  • Reply to: 'Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients'. Kristensen, Stine; Hess, Søren; Petersen, Henrik; Høilund-Carlsen, Poul // European Journal of Nuclear Medicine & Molecular Imaging;Mar2016, Vol. 43 Issue 3, p582 

    A response from S. B. Kristensen et al, to a letter to the editor about their article "Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients," from a previous issue is presented.

  • Antibodies and neuronal autoimmune disorders of the CNS. Graus, Francesc; Saiz, Albert; Dalmau, Josep // Journal of Neurology;Apr2010, Vol. 257 Issue 4, p509 

    We review the neuronal antibodies described in CNS disorders in order to clarify their diagnostic value, emphasize potentials pitfalls and limitations in the diagnosis of paraneoplastic neurological syndromes (PNS), and examine the current evidence for a possible pathogenic role. We propose to...

  • Incidence and spectrum of paraneoplastic neurological syndromes: single center study. Kanikannan, Meena; Sirisha, Y.; Uppin, Megha; Jabeen, Sheik; Kandadai, Rukmini; Sundaram, Challa; Raghunadharao, Digumarti; Borgohain, Rupam // Journal of Neuro-Oncology;Oct2015, Vol. 125 Issue 1, p197 

    Paraneoplastic neurological syndromes (PNS) are remote effects of cancer. They are much less common, but are nevertheless important because they cause severe neurological morbidity and mortality. The present cases were studied to characterize the clinical features of patients of suspected PNS...

  • Anti-Ma and anti-TA associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. Hoffman, L. A.; Jarius, S.; Pellkofer, H. L.; Schueeler, M.; Krumbholz, M.; Koenig, F.; Johannis, W.; la Fougere, C.; Newman, T.; Vincent, A.; Voltz, R. // Journal of Neurology, Neurosurgery & Psychiatry;Jul2008, Vol. 79 Issue 7, p767 

    Background: Paraneoplastic neurological syndromes (PNS) are indirect remote effects of cancer on the nervous system, often associated with the presence of specific serum antibodies. The most recently described PNS defining reactivity is anti-Ma/anti-Ta. Here we present 22 newly diagnosed...

  • Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurologicalsyndromes. F van Broekhoven // Journal of Neurology, Neurosurgery & Psychiatry;Dec2010, Vol. 81 Issue 12, p1341 

    OBJECTIVE: Paraneoplastic neurological syndromes associated with anti-Hu antibodies (Hu-PNS) are mediated by a T-cell immune response that is directed against the Hu antigens. In pregnancy, many Th1-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis regress. We...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics